Mucosal Impedance and Eosinophilic Esophagitis
This trial is active, not recruiting.
|Start date||September 2013|
|End date||July 2017|
|Trial size||60 participants|
|Trial identifier||NCT01953575, 13-005778|
Do patients with eosinophilic esophagitis have baseline increased esophageal mucosal impedance?
And will treatment that reverses esophageal eosinophilia in patients, correct abnormalities in mucosal impedance?
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
Effective treatment is defined by the elimination of esophageal eosinophilia on follow up endoscopic biopsy.
time frame: basesline to one year
Male or female participants from 18 years up to 90 years old.
Inclusion criteria: - Adults ages 18-90 undergoing clinically indicated upper endoscopy - Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field on esophageal biopsy despite at least 6 weeks of twice daily proton pump inhibitor therapy - Patients undergoing clinically indicated upper endoscopy for indications other than dysphagia or GERD with normal appearing esophageal mucosa. Exclusion criteria: - Medical conditions such as severe heart or lung disease that preclude safe performance of endoscopy - Patients with conditions known to be associated with esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome - Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy
|Official title||Mucosal Impedance in Eosinophilic Esophagitis and the Effect of Treatment|
|Principal investigator||David Katzka, MD|
Call for more information